Celanese Secures Grant Award For Research On Contraceptive Technology

Celanese Corp CE has received a grant from the Bill & Melinda Gates Foundation to produce and characterize a working prototype for a refillable contraceptive implant.
CE expects the project to produce a functional prototype that meets all established project parameters within an 18-month timeframe.
Through this grant, Celanese will provide critical research and development activities to facilitate and accelerate access to long-acting contraceptive options.
"The project concept is based on our VitalDose® drug delivery platform, a controlled release technology with decades of commercial use in the US and Europe," commented Laura Brand, VP of the Celanese medical and pharmaceutical business.
Price Action: CE shares are trading lower by 0.04% at $115.95 on the last check Wednesday.

Momentum6.94

Growth16.12

Quality-

Value32.26

Short

Medium

Long